# Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis

> **NCT04459871** · PHASE3 · COMPLETED · sponsor: **Suzhou Zelgen Biopharmaceuticals Co.,Ltd** · enrollment: 348 (actual)

## Conditions studied

- Surgical Hemostasis

## Interventions

- **BIOLOGICAL:** recombinant human Thrombin(CHO cell)
- **BIOLOGICAL:** placebo

## Key facts

- **NCT ID:** NCT04459871
- **Lead sponsor:** Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-11
- **Primary completion:** 2021-10-20
- **Final completion:** 2021-10-20
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2022-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04459871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04459871, "Safety and Efficacy of Topical Recombinant Human Thrombin(rhThrombin) for Surgical Hemostasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04459871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*